Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
:INO
RESEARCH TOOLSreports
Holding INO?
Track your performance easily
INO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.74 - $14.75
Previous CloseN/A
Volume1.36M
Average Volume (3M)1.46M
Market Cap
$68.95M
Enterprise Value$90.29M
Total Cash (Recent Filing)$104.77M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Mar 04, 2025EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.48
Shares Outstanding36,099,990
10 Day Avg. Volume1,445,874
30 Day Avg. Volume1,460,134
Standard Deviation0.29
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)238.66
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue443.89
Enterprise Value/Gross Profit108.52
Enterprise Value/Ebitda-0.82
Forecast
1Y Price Target
$10.50Price Target Upside449.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Inovio Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe overall clinical response was 81%, with a significant number of patients experiencing a decrease in surgical interventions after INO-3107 administration.
Financial PerformanceInovio reported 3Q results ahead of expectations due to lower-than-anticipated expenses.
Regulatory ProgressINO-3107 has been granted Breakthrough Therapy designation and is likely qualified for priority review, which could potentially lead to regulatory approval in late 2025 or early 2026.
Bears Say
Capital RaisingThe company may need to raise additional capital as current capital is expected to fund operations only into 3Q25.
Market ValuationThe estimated market value of the firm has decreased to $182M, or approximately $5 per share, leading to a Neutral rating with a 12-month price target adjustment to $5 from $12.
Stock RatingAnalyst reiterates a Neutral rating while adjusting the 12-month price target to $3 from $5 per share.
---
Ownership Overview
0.61% Insiders
6.92% Mutual Funds
0.18% Other Institutional Investors
85.12% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $1.74 and its highest was $14.75 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $68.95M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Nov 14, 2024. The company reported -$0.89 earnings per share for the quarter, beating the consensus estimate of -$1.15 by $0.26.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.84.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 36,099,990 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.89 in its last earnings report, beating expectations of -$1.15. Following the earnings report the stock price went down -10.692%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Among the largest hedge funds holding Inovio Pharmaceuticals’s share is GMT Capital Corp. It holds Inovio Pharmaceuticals’s shares valued at 729K.
---
Inovio Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (449.74% Upside)
$10.50 (449.74% Upside)
Blogger Sentiment
Bullish
INO Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 189.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.81%
12-Months-Change
Fundamentals
Return on Equity
-106.64%
Trailing 12-Months
Asset Growth
-44.56%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
---
INO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant progress on the lead product candidate INO-3107 and financial discipline, though challenges remain with a manufacturing issue and cash runway concerns.Read More>---
INO Stock 12 Month Forecast
Average Price Target
$10.50
▲(449.74% Upside)
Technical Analysis
Best Analysts Covering INO
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-68.54%
reiterated a buy rating 2 months ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -68.54% per trade.
---